Ascelia Pharma AB
STO:ACE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ascelia Pharma AB
STO:ACE
|
SE |
|
Lightbridge Corp
NASDAQ:LTBR
|
US |
|
B
|
Biome Australia Ltd
ASX:BIO
|
AU |
|
Odakyu Electric Railway Co Ltd
OTC:ODERF
|
JP |
Intrinsic Value
Is ACE undervalued or overvalued?
See the intrinsic value estimate for Ascelia Pharma AB and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
ACE looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with ACE’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Ascelia Pharma AB Does
Ascelia Pharma is a Swedish biotech company that develops medicines for rare cancer-related conditions. Its lead project is Orviglance, an oral contrast agent designed to improve liver MRI scans for patients who cannot use standard gadolinium-based contrast agents, such as people with serious kidney problems. The company is still focused on development and regulatory work rather than broad commercial sales.
- Headquarters
- Sweden SE
- Employees
- 21
- IPO date
- Mar 13, 2019
Revenue & Expenses Breakdown
Ascelia Pharma AB
Earnings Waterfall
Ascelia Pharma AB
The intrinsic value for Ascelia Pharma AB (ACE) under the Base Case is hidden SEK.
Compared with the current market price of 0.52 SEK, the stock appears hidden.